Biotech Growth Trust says the time is now to buy small-cap bio stocks
In its latest analysis 2021 Review & Outlook for 2022, The Biotech Growth Trust (LON: BIOG) reveals that now is an ideal time to buy small-cap biotech stocks for long-term investors, with many companies now trading at prices lower than the net cash on their balance sheet.
This comes after what has undoubtedly been a challenging year in 2021 for both the sector and investors.
"The current dislocation provides an excellent entry point for investors"Geoffrey Hsu, the trust’s portfolio manager, believes that both biotech and healthcare valuations are currently significantly undervalued due to healthcare reform being pushed through the Senate by the Biden administration.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze